Header Image

BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule drugs that block key enzymes to treat rare diseases.

RAPIVAB FDA Approved December 2014


RAPIVAB Approved by Health Canada January 2017



RAPIVAB licensed to CSL (now Seqirus) for the treatment of influenza June 2015

Learn More

To learn more about BioCryst Pharmaceuticals please read the company’s 2015 10K annual report and 2016 proxy.

Read our annual reportRead our proxy


BioCryst's core development programs include BCX7353 and other 2nd generation oral inhibitors of plasma kallikrein for hereditary angioedema and BCX4430, a broad spectrum antiviral for hemorrhagic fevers.

Learn more about BioCryst’s broad spectrum antiviral BCX4430, a potential medical countermeasure for filoviruses.

LATEST NEWS

RECENT EVENT

March 14, 2017

BioCryst presentation & webcast at the Barclay's Conference. Webcast @ 3:20P ET


Connect to webcast